Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 6/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
| ▸ | PDE1A | P54750 | 1/20 | 0.52 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.52 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17368813 | 0.93 | PLA2G4A (0.49) | PLA2G4ACES1PDE5APDE1APDE1B | |
| SCHEMBL22452061 | 0.89 | PLA2G4A (0.46) | PLA2G4ACES1PDE5APDE1APDE1B | |
| SCHEMBL1667606 | 0.85 | ALDH1A1 (0.52) | PLA2G4ACES1MAPT | |
| SCHEMBL1667949 | 0.81 | PLA2G4A (0.64) | PLA2G4ACES1MAPTRXFP1DPP4 | |
| SCHEMBL20662525 | 0.81 | PLA2G4A (0.59) | PLA2G4ACES1MAPTRXFP1DPP4 | |
| SCHEMBL15522839 | 0.81 | HDAC1 (0.55) | PDE5APDE1APDE1BPDE1CMAPT | |
| SCHEMBL1667502 | 0.79 | ALDH1A1 (0.48) | MAPT | |
| SCHEMBL22452066 | 0.77 | PLA2G4A (0.42) | PLA2G4ACES1PDE5APDE1APDE1B | |
| SCHEMBL12548449 | 0.74 | PLA2G4A (0.59) | PLA2G4ACES1FAAH | |
| SCHEMBL1667463 | 0.74 | PLA2G4A (0.62) | PLA2G4ACES1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2022-11-17 | — | — | US | disclosed |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| US-10259801-B2 | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2019-04-16 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2018-04-19 | — | — | US | disclosed |
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2018-04-19 | — | — | US | disclosed |
| CN-104892542-A | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS | 2015-09-09 | — | — | CN | disclosed |
| CN-102647984-B | Anti-inflammatory 2-carbonylthiazoles and 2-carbonyloxazoles | AVEXXIN AS | 2015-03-25 | — | — | CN | disclosed |
| CN-103772312-A | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS | 2014-05-07 | — | — | CN | disclosed |
| CN-102647984-A | Anti-inflammatory 2-carbonylthiazoles and 2-carbonyloxazoles | AVEXXIN AS | 2012-08-22 | — | — | CN | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | PLA2G4A 1999/4885CES1 59/4885PDE5A 4275/4885 |
| US-20180105507-A1 | ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS | FOXO1, FOXO3, BCOR | PLA2G4A 446/4885CES1 1307/4885PDE5A 4475/4885 |
| US-10259801-B2 | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds | OXER1, CCL2, IL6 | PLA2G4A 589/4885CES1 534/4885PDE5A 3839/4885 |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | OXER1, CASP1, IL6 | PLA2G4A 1539/4885CES1 527/4885PDE5A 3999/4885 |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, IL1B, OXER1 | PLA2G4A 1579/4885CES1 379/4885PDE5A 3628/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | PLA2G4A 1174/4885CES1 155/4885PDE5A 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.